User:Mr. Ibrahem/Talimogene laherparepvec

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Talimogene laherparepvec
Transmission electron micrograph of an unmodified herpes simplex virus
Gene therapy
Target geneGM-CSF
VectorHerpes simplex virus 1
Clinical data
Pronunciation/təˈlɪmədʒiːn ləˌhɜːrpəˈrɛpvɛk/ tə-LIM-ə-jeen lə-HUR-pə-REP-vek
Trade namesT-Vec, Imlygic, OncoVexGM-CSF, others
AHFS/Drugs.comMonograph
MedlinePlusa616006
License data
Pregnancy
category
  • Contraindicated[1]
Routes of
administration		Injection
Drug classOncolytic virus[2]
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)

Talimogene laherparepvec (T-Vec), sold under the brand name Imlygic, is a medication used to treat melanoma that cannot be operated on.[3] Specifically it is used for melanoma within and just under the skin.[4] It is given by directly injecting into lesions.[3] It has not been shown to affected life expectancy.[4]

Common side effects include tiredness, fever, nausea, and pain at the site of injection.[3] Other side effects include may include herpes infections, cellulitis or skin death at the site of injection, vasculitis, and plamacytoma.[3] Use during pregnancy may harm the baby.[3] It should not be used in people with a severely impaired immune system.[2] It is a genetically engineered herpes virus (an oncolytic virus) which infects and multiplies inside melanoma cells, resulting in their death.[2] It also stimulates an immune response against the cancer.[2]

Talimogene laherparepvec was approved in the United States and Europe in 2015.[2][4] In the United States it may cost up to 23,000 per dose as of 2021.[5] In the United Kingdom this amount costs the NHS about £6,700.[6]

References[edit]

  1. ^ "Talimogene laherparepvec (Imlygic) Use During Pregnancy". Drugs.com. 25 December 2019. Archived from the original on 8 August 2020. Retrieved 2 April 2020.
  2. ^ a b c d e "Imlygic". Archived from the original on 19 August 2021. Retrieved 21 September 2021.
  3. ^ a b c d e f g h "Talimogene Laherparepvec Monograph for Professionals". Drugs.com. Archived from the original on 7 August 2020. Retrieved 21 September 2021.
  4. ^ a b c "Imlygic (talimogene laherparepvec)". U.S. Food and Drug Administration (FDA). Archived from the original on 9 March 2021. Retrieved 21 September 2021.
  5. ^ "Imlygic Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 April 2021. Retrieved 22 September 2021.
  6. ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1007. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Talimogene_laherparepvec&oldid=1210794556"